SCHEMBL3973327

SCHEMBL3973327

COc1cc2cc(Nc3cc(C)[nH]n3)nc(O)c2cc1Br

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AURKA O14965 13/20 0.41
AURKB Q96GD4 9/20 0.41
GSK3B P49841 4/20 0.41
SRC P12931 2/20 0.37
AXL P30530 1/20 0.37
IGF1R P08069 2/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
ATM Q13315 1/20 0.36
PIK3C3 Q8NEB9 1/20 0.36
GSK3A P49840 1/20 0.36
INSR P06213 1/20 0.35
FGFR1 P11362 1/20 0.35
KDR P35968 1/20 0.35
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3972231 0.86 AURKA (0.41) AURKAAURKBGSK3BSRCNPC1
SCHEMBL3971328 0.86 AURKA (0.40) AURKAAURKBGSK3BSRCIGF1R
SCHEMBL14520022 0.86 AURKA (0.41) AURKAAURKBGSK3BSRCNPC1
SCHEMBL3964609 0.82 AURKA (0.42) AURKAAURKBGSK3BSRCIGF1R
SCHEMBL3974804 0.82 AURKA (0.38) AURKAAURKBGSK3BSRCIGF1R
SCHEMBL3967715 0.81 SYK (0.39) AURKAAURKBGSK3BSRCFGFR1
SCHEMBL3970804 0.80 AURKA (0.41) AURKAAURKBGSK3BSRCPIK3C3
SCHEMBL3973453 0.79 SYK (0.41) AURKAAURKBGSK3BSRCIGF1R
SCHEMBL3974480 0.78 CCNA2 (0.45) AURKAAURKBGSK3BSRCIGF1R
SCHEMBL3972285 0.78 CCNA2 (0.45) AURKAAURKBGSK3BSRCIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 AURKA 1165/4885AURKB 1334/4885GSK3B 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.